literature

HIV mutation literature information.

Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.

PMID: 31169022 2019 AIDS research and human retroviruses

Abstract: Prevalence of elvitegravir-associated DRMs T66A/I/K, E92Q, S147G, and the dolutegravir-associated DRM R263K increased.

Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

PMID: 30409215 2018 AIDS research and therapy

Result: Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the HIV-1 genotype of the following patients consisted of a mixture of majority and minority drug resistance mutations: patient SG79 (PR V11I 99.9%, K20I 99.9%; RT E44D 1.3%, D67N 1.1%, L100I 1.7%, M184V 84.9%, M184I 14.8%, K219Q 2.1%, INT E157Q 99.8%), patient SG86 (RT M184V 99.8%, INT L74M 97.9%, L74I 1.9%, E92Q 86

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

PMID: 30119633 2018 Retrovirology

Abstract: EVG-resistant viruses (T66I/R263K, T66I/E157Q/R263K, and S153A/R263K) retained residual susceptibility when switched to DTG, BIC or CAB, losing T66I by week 27.

Abstract: One EVG-resistant variant (T66I) acquired L74M/G140S/S147G, L74M/E138K/S147G and H51Y with DTG CAB and BIC, respectively.

Abstract: With EVG, T66I/A, E92G/V/Q,

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.

PMID: 29462322 2018 The Journal of antimicrobial chemotherapy

Abstract: Major INSTI resistance mutations were detected only at <20% threshold, at a prevalence of 2.4% (2.5% in subtype A, 2.4% C, 0% D, 8.3% G and 2.4% in recombinants) and included T66A/I (0.7%), E92G (0.5%), Y143C/S (0.7%), S147G (0.2%) and Q148R (0.5%).

Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.

PMID: 30408827 2018 PloS one

Abstract: Transmitted INSTI mutations were present in only one case (T66I) and resistance to dolutegravir was not identified at all.

Result: According to predictions from the Stanford HIVdb, phenotypic INSTI resistance (excluding potential low level) was identified in 0.7% (6/820) of cases (Fig 3B) due to the presence of the T66I (n = 1), the G163R or K (n = 4) or the combination of T97A and E157Q (n = 1) resulting in low level resistance to elvitegravir and raltegravir.

Result: Transmitted INSTI mutations according to Stanford SDRM Worksheet for INSTI were identified in a single sequence among 820 analysed cases (0.12%), namely the major primary mutation

Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.

PMID: 29631420 2018 AIDS research and human retroviruses

Abstract: Among them, 10 harbored N155H, 4 Q148H, 2 Q148R, 2 Y143C/S, and 2 T66A/I/T, respectively.

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.

PMID: 29346270 2018 Viruses

Introduction: The addition of the E138K substitution to the T66I-R263K double-mutant partially compensated for these deficits and resulted in a high level of resistance against EVG but not against DTG or RAL.

Introduction: The aim of this study was to assess the effects of the T66I and E138K substitutions, alone and in combination with R263K, on viral replicative capacity and resistance to INI.

Introduction: They show

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

PMID: 29239896 2018 AIDS (London, England)

Result: One HIV-1B patient had a major primary INSTI-DRM, T66I (Supplementary Digital Content 1).

Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.

PMID: 28328546 2017 Journal of acquired immune deficiency syndromes (1999)

Result: Two studies reported sequencing the integrase gene in CSF; N155H, L74I, and Q148R mutations were observed as single mutations in the integrase gene, and Y143C was observed in combination with T66I.

HIV-1 integrase inhibitor resistance among treatment naive patients in the West of Scotland.

PMID: 28494325 2017 Journal of clinical virology

Abstract: RESULTS: We detected integrase inhibitor resistance (T66I/T) at baseline in one patient sample.

Browser Board

Co-occurred Entities

Filtrator